Abstract
Introduction
Antihormonal cancer therapies are a class of drugs used predominantly in the
treatment of breast cancer and prostate cancer. The high incidence of these
tumor types translates into a significant commercial potential for drug
developers. Collectively, the antihormonal therapy cancer brands generated
sales of about $6.9 billion in the seven major pharmaceutical markets in 2008.
Scope of this research
- In-depth analysis of the current and future antihormonal therapies market
across the US, 5EU and Japan, plus a rest of world snapshot
- Antihormonal therapy sales forecasts for brands and generics from 2008 to
2018
- Assessment of the leading cancer brands and drug classes to identify key
success factors within this sector
- Evaluation of the strategies of leading players in the antihormonals market
Research and analysis highlights
The antihormonals market was worth $6.9 billion in 2008 across the seven major
pharmaceutical markets. Its growth within the next decade, at a marginal CAGR
of 0.1%, will be predominantly limited by patent expiries of leading brands.
In 2008, Arimidex (anastrozole; AstraZeneca), Lupron (leuprolide;
Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca) were the three leading
antihormonal brands in terms of sales. These will remain the top three brands
through to 2018, even though Arimidex and Casodex will lose around 40% of
their brand value due to generic competition.
In a mature market, the importance of product lifecycle management is high.
AstraZeneca was the key player in the market in 2008, with an antihormonals
portfolio valued at over $3.4 billion. With successful lifecycle management
and a considerable investment in marketing activities, AstraZeneca has built a
strong brand presence for its products.
Key reasons to purchase this research
- Quantify the performance of each of the marketed antihormonal therapy
cancer brands in the seven major markets over the period 2008 to 2018
- Acquire a detailed account of antihormonal therapy cancer brand dynamics
and the events that drive and limit their market growth
- Benchmark the antihormonal therapy cancer brands against generics and rest
of class and align their 7MM performance with a rest of world snapshot
| 
View Cart
